Edition:
United States

Ocera Therapeutics Inc (OCRX.OQ)

OCRX.OQ on NASDAQ Stock Exchange Global Market

1.30USD
21 Apr 2017
Change (% chg)

$-0.03 (-2.26%)
Prev Close
$1.33
Open
$1.32
Day's High
$1.35
Day's Low
$1.30
Volume
26,128
Avg. Vol
335,801
52-wk High
$3.26
52-wk Low
$0.54

OCRX.OQ

Chart for OCRX.OQ

About

Ocera Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on acute and chronic orphan liver diseases. The Company is focused on the development and commercialization of its clinical candidate, OCR-002, for the treatment of hepatic encephalopathy (HE). OCR-002 is a molecule, ornithine... (more)

Overall

Beta: 2.17
Market Cap(Mil.): $30.68
Shares Outstanding(Mil.): 23.60
Dividend: --
Yield (%): --

Financials

  OCRX.OQ Industry Sector
P/E (TTM): -- 29.08 29.95
EPS (TTM): -1.23 -- --
ROI: -94.73 13.66 13.21
ROE: -114.13 14.61 14.38

BRIEF-Perceptive Advisors reports 9.11 pct passive stake in Ocera Therapeutics

* Perceptive Advisors Llc reports 9.11 percent passive stake in Ocera Therapeutics Inc as of March 8, 2017- sec filing Source text - http://bit.ly/2oFR2tW Further company coverage:

Apr 17 2017

BRIEF-Ocera to announce additional results from its phase 2b STOP-HE study of IV OCR-002

* Ocera to announce additional results from its phase 2b STOP-HE study of IV OCR-002 in patients with hepatic encephalopathy

Mar 08 2017

BRIEF-Ocera announces top-line results for phase 2b study in hepatic encephalopathy

* Ocera announces top-line results for phase 2b study in hepatic encephalopathy

Jan 30 2017

BRIEF-Ocera Therapeutics posts Q3 loss of $0.32/share

* Ocera Therapeutics reports third quarter 2016 financial results and company update

Nov 02 2016

More From Around the Web

Competitors

Earnings vs. Estimates